S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.32
+1.64
+9.83%
ZTS · ZOETIS INC.
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
$79.61
-0.42
(-0.52%)
● At close: October 21 at 4:00:00 PM EDT
$79.87
+0.28
(+0.35%)
Pre-Market:
4:53:04 AM EDT
DAY'S RANGE
$79.61
$78.89
$79.99
52-WEEK RANGE
$79.61
$68.77
$148.30
What's happening
- ZTS is down 0.52% today, trading at $79.61. — Live quote
- Volume today (144,896) is well below its 3-month average of 5,659,780. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (before market open), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $1.87 actual vs. $1.87 estimated (-0.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 12
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (23 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ZTS
-36.39%
vs S&P 500
-49.16%
1-YEAR RETURN
ZTS
-44.82%
vs S&P 500
-59.38%
6-MONTH RETURN
ZTS
-32.76%
3-MONTH RETURN
ZTS
+6.22%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$1.87
Est. $1.87
MISS -0.2%
2026-04-26 (Q1 2026)
$1.53
Est. $1.63
MISS -6.2%
2026-01-26 (Q4 2025)
$1.48
Est. $1.42
BEAT +4.5%
2025-10-26 (Q3 2025)
$1.70
Est. $1.64
BEAT +3.8%
Valuation Measures & Ratios
Enterprise Value4$40.48B
Forward P/E511.41
PEG Ratio62.09
Price / Sales (TTM1)3.46
Price / Book79.57
EV4 / Revenue4.25
EV4 / EBITDA11.92
Profit Margin27.49%
Operating Margin34.38%
Return on Equity (ROE8)69.25%
Return on Assets (ROA9)17.19%
Avg Volume (3M)5,659,780
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $29.88B | $49.43B | $63.53B | $67.91B | $72.09B |
| P/E | 10.91 | 18.65 | 23.26 | 25.78 | 28.76 |
| Price/Sales | 3.11 | 5.30 | 6.72 | 7.21 | 7.89 |
| Price/Book | 9.49 | 15.29 | 11.77 | 13.64 | 15.49 |
| EV/Revenue | 3.90 | 6.06 | 7.24 | 7.61 | 8.27 |
| ROE | 87.01% | 81.97% | 50.59% | 52.92% | 53.86% |
| ROA | 18.17% | 17.49% | 18.02% | 18.19% | 17.78% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,424,459
Change from Prior Settlement+5.95%
% of Float—
Days to Cover (Short Ratio)4.09
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 0.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 27.5%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -44.8%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ZTS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.47B | $2.26B | $2.40B | $2.47B | $2.20B | $2.39B | $2.36B | $2.19B |
| Net income | $691.0M | $601.0M | $721.0M | $726.0M | $602.0M | $682.0M | $624.0M | $599.0M |
| EPS (diluted) | $1.65 | $1.42 | $1.63 | $1.63 | $1.34 | $1.50 | $1.37 | $1.31 |
| EPS (basic) | $1.65 | $1.42 | $1.63 | $1.63 | $1.34 | $1.51 | $1.37 | $1.31 |
| Net margin | $28 | $27 | $30 | $29 | $27 | $29 | $26 | $27 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $15.08B | $15.15B | $15.49B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B |
| Total liabilities | $11.93B | $11.92B | $12.07B | $9.76B | $9.50B | $9.44B | $9.47B | $9.12B |
| Stockholders' equity | $3.15B | $3.23B | $3.42B | $5.40B | $4.98B | $4.66B | $4.77B | $5.23B |
| Total current assets | $6.36B | $6.47B | $6.77B | $6.58B | $5.92B | $5.88B | $5.99B | $6.28B |
| Total current liabilities | $2.06B | $2.05B | $2.17B | $1.81B | $3.37B | $3.38B | $3.41B | $1.70B |
| Cash & equivalents | $1.48B | $1.94B | $2.45B | $2.08B | $1.44B | $1.72B | $1.99B | $1.71B |
| Marketable securities (current) | $200.0M | — | $0 | — | — | — | — | — |
| Accounts receivable | $1.57B | $1.51B | $1.41B | $1.54B | $1.54B | $1.36B | $1.32B | $1.41B |
| Inventory | $2.57B | $2.55B | $2.46B | $2.46B | $2.44B | $2.37B | $2.31B | $2.42B |
| Other current assets | $535.0M | $477.0M | $450.0M | $493.0M | $509.0M | $430.0M | $377.0M | $427.0M |
| Property, plant & equipment | $3.76B | $3.72B | $3.69B | $3.60B | $3.54B | $3.44B | $3.39B | $3.30B |
| Goodwill | $2.77B | $2.78B | $2.77B | $2.76B | $2.76B | $2.72B | $2.72B | $2.74B |
| Intangible assets | $918.0M | $959.0M | $998.0M | $1.04B | $1.07B | $1.08B | $1.13B | $1.19B |
| Other non-current assets | $384.0M | $351.0M | $327.0M | $293.0M | $267.0M | $232.0M | $250.0M | $215.0M |
| Accounts payable | $452.0M | $507.0M | $445.0M | $410.0M | $508.0M | $420.0M | $433.0M | $404.0M |
| Accrued liabilities | — | — | $852.0M | — | — | — | $746.0M | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current liabilities | $125.0M | $121.0M | $109.0M | $99.0M | $130.0M | $117.0M | $125.0M | $115.0M |
| Long-term debt | $9.05B | $9.04B | $9.04B | $7.07B | $5.23B | $5.23B | $5.22B | $6.57B |
| Other non-current liabilities | $220.0M | $219.0M | $250.0M | $264.0M | $274.0M | $220.0M | $222.0M | $220.0M |
| Common stock & paid-in capital | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M |
| Retained earnings | $14.65B | $14.18B | $13.80B | $13.59B | $12.87B | $12.38B | $11.97B | $11.81B |
| Accumulated other comprehensive income (loss) | -$796.0M | -$772.0M | -$804.0M | -$818.0M | -$877.0M | -$1.02B | -$940.0M | -$851.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $655.0M | $401.0M | $893.0M | $891.0M | $605.0M | $515.0M | $905.0M | $951.0M |
| Investing cash flow | -$300.0M | -$87.0M | -$166.0M | -$167.0M | -$212.0M | -$203.0M | $126.0M | -$178.0M |
| Financing cash flow | -$813.0M | -$840.0M | -$495.0M | -$134.0M | -$564.0M | -$677.0M | -$745.0M | -$628.0M |
| Free cash flow | $538.0M | $291.0M | $732.0M | $755.0M | $459.0M | $337.0M | $689.0M | $784.0M |
| Capital expenditures | $117.0M | $110.0M | $161.0M | $136.0M | $146.0M | $178.0M | $216.0M | $167.0M |
| Depreciation & amortization | $119.0M | $119.0M | $368.0M | $124.0M | $124.0M | $119.0M | $371.0M | $121.0M |
| Share-based compensation | $26.0M | $25.0M | $22.0M | $22.0M | $22.0M | $17.0M | $19.0M | $18.0M |
| Deferred income taxes | -$33.0M | $34.0M | -$48.0M | -$16.0M | -$2.0M | $14.0M | -$152.0M | -$42.0M |
| Change in accounts receivable | $66.0M | $106.0M | $52.0M | $32.0M | $106.0M | $46.0M | -$73.0M | $22.0M |
| Change in inventory | $23.0M | $114.0M | -$13.0M | $45.0M | $82.0M | $85.0M | -$73.0M | -$2.0M |
| Change in accounts payable | -$53.0M | $62.0M | $76.0M | -$45.0M | -$7.0M | $22.0M | $26.0M | -$15.0M |
| Purchases of investments | $206.0M | $2.0M | $1.0M | $3.0M | $1.0M | $2.0M | $1.0M | $1.0M |
| Other investing activities | -$2.0M | $1.0M | $1.0M | $0 | -$1.0M | -$1.0M | $0 | $0 |
| Share repurchases | $584.0M | $606.0M | $1.53B | $394.0M | $338.0M | $443.0M | $553.0M | $433.0M |
| Debt repaid | — | — | $0 | $1.35B | — | — | $0 | $0 |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
| Other financing activities | -$1.0M | -$3.0M | $0 | -$2.0M | $0 | -$1.0M | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Net income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| EPS (diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| EPS (basic) | $6.03 | $5.47 | $5.08 | $4.51 | $4.29 |
| Net margin | $28 | $27 | $27 | $26 | $26 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $15.47B | $14.24B | $14.29B | $14.93B | $13.90B |
| Total liabilities | $12.14B | $9.47B | $9.29B | $10.52B | $9.36B |
| Stockholders' equity | $3.33B | $4.77B | $5.00B | $4.41B | $4.54B |
| Total current assets | $6.77B | $5.99B | $6.34B | $7.51B | $6.93B |
| Total current liabilities | $2.23B | $3.41B | $1.89B | $3.17B | $1.80B |
| Cash & equivalents | — | — | — | — | — |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $1.59B | $1.32B | $1.30B | $1.22B | $1.13B |
| Inventory | $2.43B | $2.31B | $2.56B | $2.35B | $1.92B |
| Other current assets | $436.0M | $377.0M | $434.0M | $365.0M | $389.0M |
| Property, plant & equipment | $3.68B | $3.39B | $3.20B | $2.75B | $2.42B |
| Goodwill | $2.77B | $2.72B | $2.76B | $2.75B | $2.68B |
| Intangible assets | $998.0M | $1.13B | $1.34B | $1.38B | $1.47B |
| Other non-current assets | $328.0M | $250.0M | $206.0M | $147.0M | $111.0M |
| Accounts payable | $487.0M | $433.0M | $411.0M | $405.0M | $436.0M |
| Accrued liabilities | $852.0M | $746.0M | $683.0M | $682.0M | $710.0M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | $0 | $0 | $0 | $0 | $0 |
| Other current liabilities | $107.0M | $125.0M | $102.0M | $97.0M | $67.0M |
| Long-term debt | $9.04B | $5.22B | $6.56B | $6.55B | $6.59B |
| Other non-current liabilities | $248.0M | $222.0M | $237.0M | $217.0M | $239.0M |
| Common stock & paid-in capital | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M |
| Retained earnings | $13.74B | $11.97B | $10.29B | $8.67B | $7.19B |
| Accumulated other comprehensive income (loss) | -$834.0M | -$940.0M | -$839.0M | -$817.0M | -$764.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $2.90B | $2.95B | $2.35B | $1.91B | $2.21B |
| Investing cash flow | -$748.0M | -$315.0M | -$777.0M | -$883.0M | -$458.0M |
| Financing cash flow | -$1.87B | -$2.66B | -$3.11B | -$904.0M | -$1.86B |
| Free cash flow | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B |
| Capital expenditures | $621.0M | $655.0M | $732.0M | $586.0M | $477.0M |
| Depreciation & amortization | $487.0M | $497.0M | $491.0M | $465.0M | $448.0M |
| Share-based compensation | $83.0M | $74.0M | $60.0M | $62.0M | $58.0M |
| Deferred income taxes | -$52.0M | -$338.0M | -$61.0M | -$286.0M | -$80.0M |
| Change in accounts receivable | $236.0M | $61.0M | $102.0M | $137.0M | $155.0M |
| Change in inventory | $199.0M | $40.0M | $361.0M | $486.0M | $366.0M |
| Change in accounts payable | $46.0M | $31.0M | $13.0M | -$29.0M | -$17.0M |
| Purchases of investments | $7.0M | $5.0M | $4.0M | $9.0M | $12.0M |
| Other investing activities | -$1.0M | $2.0M | -$6.0M | $0 | $1.0M |
| Share repurchases | $3.23B | $1.86B | $1.09B | $1.59B | $743.0M |
| Debt repaid | $1.35B | $0 | $1.35B | $0 | $600.0M |
| Other financing activities | -$3.0M | $0 | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ZTS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-20 to 2026-09-30
Recent transactions
- Most recent: FULLER JULIE (Executive Vice President) — Option exercise of 799 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| FULLER JULIE | Executive Vice President | Option exercise | 2026-09-30 | 799 |
| DAMELIO FRANK A | Director | Gift | 2026-08-07 | 6,650 |
| MCCALLISTER MICHAEL B | Director | Gift | 2026-06-10 | 1,209 |
| Stetter Mark | Director | Option exercise | 2026-05-21 | 1,572 |
| PARENT LOUISE M | Director | Option exercise | 2026-05-20 | 1,944 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | FULLER JULIE | Executive Vice President | Option exercise | 799 | — |
| 2026-09-30 | FULLER JULIE | Executive Vice President | Tax withholding | 274 | $69.83 |
| 2026-08-07 | DAMELIO FRANK A | Director | Gift | 6,650 | $0.00 |
| 2026-06-10 | MCCALLISTER MICHAEL B | Director | Gift | 1,209 | $0.00 |
| 2026-05-21 | Stetter Mark | Director | Option exercise | 1,572 | — |
| 2026-05-20 | PARENT LOUISE M | Director | Option exercise | 1,944 | — |
| 2026-05-20 | PARENT LOUISE M | Director | Option exercise | 10,186 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:59 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-10-08 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
Recent news
Headlines about ZTS (ZOETIS INC.). Links open the publisher — we don’t host full articles.
-
How Unusual Is Zoetis's Latest Sales Growth?
Yahoo · 2026-10-22 -
SPHQ, QUAL, and MOAT Define Quality Differently. Those Rules Decide What You Own
Yahoo · 2026-10-22 -
Zoetis Inc. (ZTS) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Yahoo · 2026-10-21 -
Zoetis (ZTS) Gains FDA Approval for Convenia RTU for Dogs, Enhan
GuruFocus · 2026-10-20 -
Zoetis: Weakening Fundamentals Overshadow The Discount (NYSE:ZTS)
Seeking Alpha · 2026-10-20 -
FDA approves Zoetis’ Convenia RTU for canine skin infections By Investing.com
Investing.com Canada · 2026-10-20 -
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Yahoo · 2026-10-20
No headlines in this category right now — try “All”.